Vyome Holdings Inc. Common Stock (HIND)
Stock · NASDAQ · Health Care
$1.87as of 10/16/2026
Price chart
Active signals
HIND Signal Track Record
How signals performed across all stocks →What HIND's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 27 | -17.9% | 30% | September 8, 2026 |
| Bollinger Band Breakout | 18 | -33.7% | 6% | May 26, 2026 |
| Volume Spike | 11 | -20.4% | 36% | September 21, 2026 |
| Any 20-session window (baseline) | -14.5% | 25% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HIND
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treat…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 9
Fundamentals
- 1-day range
- $1.83$1.93
- Market cap
- $15.02M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-3.51
- Dividend yield
- —
- Beta
- 1.58
- Avg. volume
- 12.7K
How Vyome Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Apr 4, 2025 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Vyome Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HINDVyome Holdings Inc. Common Stock$1.87▼ 2.09%Market cap $15.02MP/E —$1.75$6.56
- SCNXScienture Holdings Inc. Common Stock$3.36▼ 0.59%Market cap $15.14MP/E —$3.21$65
- KTTAPasithea Therapeutics Corp. Common Stock$0.42▲ 2.44%Market cap $14.82MP/E —$0.281$2.06
- TPSTTempest Therapeutics Inc. Common Stock$0.624▼ 1.73%Market cap $14.42MP/E —$0.6801$12.23
- KALAKALA BIO Inc. Common Stock$0.19▼ 1.04%Market cap $14.25MP/E —$0.2593$95.5
- COCPCocrystal Pharma Inc. Common Stock$1.02▼ 0.97%Market cap $14.20MP/E —$0.76$2.03
- AKTXAkari Therapeutics plc ADS$8.18▼ 7.47%Market cap $14.14MP/E Infinity$3.02$39.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HIND Vyome Holdings Inc. Common Stock | $15.02M | — | $1.87 | ▼ 2.09% | $1.75$6.56 |
| SCNX Scienture Holdings Inc. Common Stock | $15.14M | — | $3.36 | ▼ 0.59% | $3.21$65 |
| KTTA Pasithea Therapeutics Corp. Common Stock | $14.82M | — | $0.42 | ▲ 2.44% | $0.281$2.06 |
| TPST Tempest Therapeutics Inc. Common Stock | $14.42M | — | $0.624 | ▼ 1.73% | $0.6801$12.23 |
| KALA KALA BIO Inc. Common Stock | $14.25M | — | $0.19 | ▼ 1.04% | $0.2593$95.5 |
| COCP Cocrystal Pharma Inc. Common Stock | $14.20M | — | $1.02 | ▼ 0.97% | $0.76$2.03 |
| AKTX Akari Therapeutics plc ADS | $14.14M | Infinity | $8.18 | ▼ 7.47% | $3.02$39.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation MarketYahoo · 10/5/2026
- Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".benzinga · 9/18/2026
- Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".Benzinga · 9/18/2026
- Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial OfficerYahoo · 9/14/2026
- Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025Benzinga · 9/14/2026
Insider Activity
Insider Actions →- Mohanjit Jolly · September 1, 2026 · Grant120.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 79.8K
- Total value held
- $172.1K
- Institutional holders
- 8
- Unknown25.8K
- Unknown22.7K
- Unknown14.6K
- Unknown9.5K
- Unknown5.9K
- Unknown1.4K
- Unknown16
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vyome Holdings Gets USPTO Patent Allowance for VT-1908
Vyome Holdings received a USPTO notice of allowance for a U.S. patent covering its VT-1908 topical mycophenolate program. This development relates to a treatment targeting the ocular inflammation market, which is valued at over $20 billion. The stock is currently trading near its 52-week low, with analysts averaging a higher target price.
Vyome Holdings Gets USPTO Patent Allowance for VT-1908. Vyome Holdings received a USPTO notice of allowance for a U.S. patent covering its VT-1908 topical mycophenolate program. This development relates to a treatment targeting the ocular inflammation market, which is valued at over $20 billion. The stock is currently trading near its 52-week low, with analysts averaging a higher target price.